# Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

> **NCT04723537** · PHASE2,PHASE3 · TERMINATED · sponsor: **RedHill Biopharma Limited** · enrollment: 61 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Part A: Upamostat 200 mg
- **DRUG:** Part A: Upamostat 400 mg
- **DRUG:** Part A and B: Placebo
- **DRUG:** Part B: Upamostat 200 or 400 mg

## Key facts

- **NCT ID:** NCT04723537
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-16
- **Primary completion:** 2021-12-28
- **Final completion:** 2021-12-28
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Part A complete; corporate decision made to cancel Part B.
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04723537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04723537, "Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04723537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*